| Prev Close: | 8.06 |
|---|---|
| Open: | 8.01 |
| Bid: | 8.25 x 1500 |
| Ask: | 8.30 x 2900 |
| 1y Target Est: | 8.36 |
| Beta: | -0.54 |
| Next Earnings Date: | 7-Aug-13 |
| Day's Range: | 8.01 - 8.36 |
|---|---|
| 52wk Range: | 6.01 - 13.50 |
| Volume: | 6,433,731 |
| Avg Vol (3m): | 5,349,840 |
| Market Cap: | 1.81B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.37 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why This Obesity Drug Is the Sector's Best Betat Motley Fool(Fri, May 24)
- Arena Pharmaceuticals to Present at Two Upcoming Investor ConferencesPR Newswire(Fri, May 24)
- Novo obesity drug could launch in U.S. end 2014at Reuters(Fri, May 24)
- Arena - Good Sales, Bad Sales, Long And Shortat Seeking Alpha(Fri, May 24)
- First Manhattan Still Playing Hardball With Vivusat Seeking Alpha(Fri, May 24)
- Arena Is Still A Great Shortat Seeking Alpha(Thu, May 23)
- Arena Buyout More 'Highly Probable' Than MannKindat Seeking Alpha(Thu, May 23)
- Why Doctors Can Prescribe Arena's Belviq For Off Label Uses Without Worrying About Legal Liabilityat Seeking Alpha(Wed, May 22)
- 3 Pipeline Obesity Treatments You Should Watchat Motley Fool(Wed, May 22)
- Arena Pharmaceuticals - Out To Launch Or Out To Lunch?at Seeking Alpha(Wed, May 22)
- The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Doesat Seeking Alpha(Tue, May 21)
- The 9 Most Obese Countries in the Worldat Motley Fool(Mon, May 20)
- Arena NOLs Will Come Into Play Soonat Seeking Alpha(Mon, May 20)
- Vivus Taps Into More Cashat Seeking Alpha(Sun, May 19)
- 25 Belt-Busting Obesity Factsat Motley Fool(Sat, May 18)
Press Releases
- Arena Pharmaceuticals to Present at Two Upcoming Investor ConferencesPR Newswire(Fri, May 24)
- Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Fri, May 10)
- Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ® (lorcaserin HCl) for Chronic Weight ManagementPR Newswire(Tue, May 7)
Reports
- ARNA - Arena Pharmaceuticals Inc - Downgraded to a Sell - Company Analysis and...Alpha Street Research(May 28)
- ARNA PHARMACEUTICALS INC (ARNA) 12-months forecastPechala's Reports(May 25)
- ARNA: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 24)